-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $29

Benzinga·12/02/2025 15:18:17
Listen to the news
Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $24 to $29.